Search

Your search keyword '"Robey, Robert W."' showing total 519 results

Search Constraints

Start Over You searched for: Author "Robey, Robert W." Remove constraint Author: "Robey, Robert W."
519 results on '"Robey, Robert W."'

Search Results

6. Improving Fortran Performance Portability

7. Supplemental Table S5 from The Methyltransferases METTL7A and METTL7B Confer Resistance to Thiol-Based Histone Deacetylase Inhibitors

8. Figure S3 from The Methyltransferases METTL7A and METTL7B Confer Resistance to Thiol-Based Histone Deacetylase Inhibitors

9. Data from The Methyltransferases METTL7A and METTL7B Confer Resistance to Thiol-Based Histone Deacetylase Inhibitors

10. Carrier‐Free, Amorphous Verteporfin Nanodrug for Enhanced Photodynamic Cancer Therapy and Brain Drug Delivery

13. The Methyltransferases METTL7A and METTL7B Confer Resistance to Thiol-Based Histone Deacetylase Inhibitors

14. Mitochondrial ATP fuels ABC transporter-mediated drug efflux in cancer chemoresistance

15. Characterization and tissue localization of zebrafish homologs of the human ABCB1 multidrug transporter

17. ForOpenCL: Transformations Exploiting Array Syntax in Fortran for Accelerator Programming

21. List of Contributors

22. Combined inhibition of TOP1 and PARP: a synergistic therapeutic strategy for glioblastoma with PTEN deficiency

23. Exploiting the therapeutic vulnerability of IDH-mutant gliomas with zotiraciclib

24. The ABCG2 Multidrug Transporter

27. Data from R-Loop–Mediated ssDNA Breaks Accumulate Following Short-Term Exposure to the HDAC Inhibitor Romidepsin

28. Data from Rigosertib Induces Mitotic Arrest and Apoptosis in RAS-Mutated Rhabdomyosarcoma and Neuroblastoma

29. Supplementary Data from Rigosertib Induces Mitotic Arrest and Apoptosis in RAS-Mutated Rhabdomyosarcoma and Neuroblastoma

30. Supplementary Data from R-Loop–Mediated ssDNA Breaks Accumulate Following Short-Term Exposure to the HDAC Inhibitor Romidepsin

31. Supplementary Figure S2 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models

32. Supplementary Data File S5 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models

33. Supplementary Data from A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer

37. Data from Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2

48. Supplementary Figures 1-2 from Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2

50. Novel Therapeutic Strategies Exploiting the Unique Properties of Neuroendocrine Neoplasms

Catalog

Books, media, physical & digital resources